The Cancer Letter

Inside information on cancer research and drug development

In Brief

Bayer Pharma and Ventana enter agreement

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

VENTANA MEDICAL SYSTEMS INC. has entered into a multi-year agreement with Bayer Pharma AG to develop companion diagnostics with a focus on immunohistochemistry, across Bayer’s portfolio of targeted therapy projects.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Login

Site license subscribers:
Log in with your IP | Register a sponsored account